43.15

1.65% 0.70

After Hours: 43.76 0.61 +1.41%

Xenon Pharmaceuticals Inc (XENE)

Overview News Price History Option Chain Financials Discussions Forecast

Xenon Pharmaceuticals Inc stock is traded at $43.15, with a volume of 391.58K. It is up +1.65% in the last 24 hours and up +3.40% over the past month. Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Previous Close:

$42.45

Open:

$42.46

24h Volume:

391.58K

Relative Volume:

1.16

Market Cap:

$3.26B

Revenue:

$13.17M

Net Income/Loss:

$-199.06M

P/E Ratio:

-17.33

EPS:

-2.49

Net Cash Flow:

$-156.53M

1W Performance:

+9.68%

1M Performance:

+3.40%

6M Performance:

+12.46%

1Y Performance:

+26.47%

1-Day Range:

$42.06

$43.41

1-Week Range:

$38.71

$43.41

52-Week Range:

$33.62

$50.99

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name

Xenon Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(604) 484-3300

Address

200 - 3650 GILMORE WAY, BURNABY

Employee

259

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

XENE's Discussions on Twitter

Compare XENE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XENE Xenon Pharmaceuticals Inc	43.15	3.26B	13.17M	-199.06M	-156.53M	-2.49
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-24	Resumed	Raymond James	Outperform
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jan-04-24	Initiated	Citigroup	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight
Dec-14-22	Initiated	Goldman	Buy
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight
Oct-19-22	Initiated	Raymond James	Outperform
Aug-29-22	Initiated	BofA Securities	Buy
Jul-21-22	Initiated	JP Morgan	Overweight
Oct-28-21	Initiated	RBC Capital Mkts	Outperform
Oct-02-20	Initiated	SVB Leerink	Outperform
Jul-21-20	Initiated	Needham	Buy
Jun-01-20	Resumed	Jefferies	Buy
Mar-25-20	Initiated	Wedbush	Outperform
Jan-08-20	Initiated	William Blair	Outperform
Sep-20-19	Initiated	Guggenheim	Buy
Aug-08-18	Reiterated	Stifel	Buy
Mar-13-17	Initiated	Jefferies	Buy
Oct-21-16	Initiated	Stifel	Buy
Sep-26-16	Initiated	Guggenheim	Buy
Apr-14-16	Reiterated	Jefferies	Buy
Oct-30-15	Resumed	Jefferies	Buy
Dec-02-14	Initiated	Canaccord Genuity	Buy

View All

Xenon Pharmaceuticals Inc Stock (XENE) Latest News

Nov 27, 2024

Natixis Advisors LLC Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

Nov 27, 2024

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Nov 27, 2024

Nov 26, 2024

(XENE) Trading Signals - Stock Traders Daily

Nov 26, 2024

Loomis Sayles & Co. L P Buys 46,964 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Nov 26, 2024

Nov 25, 2024

Xenon Pharmaceuticals' SWOT analysis: stock poised for breakthrough in epilepsy - Investing.com

Nov 25, 2024

Xenon Pharmaceuticals Unveils New Data at AES 2024 - TipRanks

Nov 25, 2024

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 - The Manila Times

Nov 25, 2024

Westfield Capital Management Co. LP Buys 26,054 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Nov 25, 2024

Nov 24, 2024

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Nov 24, 2024

Nov 23, 2024

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Sells $200,922.28 in Stock - MarketBeat

Nov 23, 2024

Xenon Pharmaceuticals director sells $200,946 in stock - Investing.com India

Nov 23, 2024

Nov 22, 2024

Xenon Pharmaceuticals director sells $200,946 in stock By Investing.com - Investing.com Nigeria

Nov 22, 2024

Nov 19, 2024

First Turn Management LLC Sells 14,658 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Investors Eye Opportunities With Xenon Pharmaceuticals - Evrim Ağacı

Nov 18, 2024

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap DownHere's What Happened - MarketBeat

Nov 18, 2024

Needham & Company LLC Reaffirms Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World

Nov 15, 2024

Nov 14, 2024

Stock Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat

Nov 14, 2024

GSA Capital Partners LLP Purchases 30,830 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Nov 14, 2024

Nov 13, 2024

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - MSN

Nov 13, 2024

Xenon to Present at Upcoming Investor Conferences - The Manila Times

Nov 13, 2024

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results - MarketBeat

Nov 13, 2024

Needham & Company LLC Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat

Nov 13, 2024

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Xenon Pharmaceuticals: Q3 Earnings Snapshot - mySA

Nov 13, 2024